Efficacy and Safety Results of the Sierra Trial: A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/22365

The link includes a list of those medical professionals who authored the Late Breaking Abstract of Iomab-B back in 2023. A message was sent out to each of them to ask for their support of the petition.

Please also feel free to reach out to these professionals to further advocate support for the petition.